SEC Comment Letter for CTI BIOPHARMA CORP (CIK 0000891293) — Dec 16, 2020
CTI BIOPHARMA CORP (CIK 0000891293)
Date: Dec. 16, 2020 · CIK: 0000891293 · Accession: 0000000000-20-012100
AI Filing Summary & Sentiment
File numbers found in text: 333-251161
Letter
United States securities and exchange commission logo December 11, 2020 Adam Craig, M.D., Ph.D. Chief Executive Officer CTI BioPharma Corp. 3101 Western Avenue, Suite 800 Seattle, WA 98121 Re:CTI BioPharma Corp. Registration Statement on Form S-3 Filed December 7, 2020 File No. 333-251161 Dear Dr. Craig: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason L. Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ryan Murr, Esq.
Show Raw Text
United States securities and exchange commission logo
December 11, 2020
Adam Craig, M.D., Ph.D.
Chief Executive Officer
CTI BioPharma Corp.
3101 Western Avenue, Suite 800
Seattle, WA 98121
Re:CTI BioPharma Corp.
Registration Statement on Form S-3
Filed December 7, 2020
File No. 333-251161
Dear Dr. Craig:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason L. Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Ryan Murr, Esq.